X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1527) 1527
Publication (93) 93
Book Review (29) 29
Book Chapter (9) 9
Book / eBook (4) 4
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1190) 1190
index medicus (860) 860
male (765) 765
female (698) 698
middle aged (558) 558
platelet function tests (545) 545
platelet-function (483) 483
hematology (451) 451
aged (414) 414
adult (352) 352
platelet aggregation - drug effects (350) 350
peripheral vascular disease (343) 343
aspirin (329) 329
blood platelets - drug effects (313) 313
clopidogrel (304) 304
platelet aggregation inhibitors - therapeutic use (275) 275
cardiac & cardiovascular systems (272) 272
ticlopidine - analogs & derivatives (271) 271
platelet function (228) 228
treatment outcome (227) 227
platelets (213) 213
blood platelets - metabolism (212) 212
aggregation (204) 204
risk factors (204) 204
animals (202) 202
platelet aggregation (195) 195
myocardial-infarction (189) 189
percutaneous coronary intervention (187) 187
platelet aggregation inhibitors - pharmacology (187) 187
prospective studies (183) 183
thrombosis (179) 179
blood platelets (177) 177
platelet aggregation inhibitors - administration & dosage (167) 167
aspirin - therapeutic use (165) 165
antiplatelet therapy (153) 153
pharmacology & pharmacy (151) 151
ticlopidine - therapeutic use (145) 145
analysis (144) 144
drug resistance (140) 140
time factors (140) 140
care and treatment (139) 139
risk (139) 139
inhibition (134) 134
platelet function tests - methods (130) 130
activation (122) 122
blood platelets - physiology (122) 122
cardiology (121) 121
platelet aggregation inhibitors - adverse effects (120) 120
coronary heart disease (114) 114
hemostasis (112) 112
coagulation (108) 108
ticlopidine - administration & dosage (108) 108
aspirin resistance (106) 106
blood (106) 106
cardiac patients (105) 105
drug therapy, combination (102) 102
platelet activation - drug effects (101) 101
resistance (101) 101
dose-response relationship, drug (100) 100
surgery (100) 100
cardiovascular disease (97) 97
aged, 80 and over (96) 96
aspirin - pharmacology (95) 95
coronary artery disease - drug therapy (90) 90
disease (90) 90
aspirin - administration & dosage (88) 88
cardiovascular (88) 88
acute coronary syndromes (87) 87
cardiovascular-disease (87) 87
coronary-artery-disease (86) 86
double-blind method (86) 86
drug therapy (85) 85
medicine & public health (85) 85
platelet activation (84) 84
therapy (84) 84
platelet count (83) 83
prasugrel (83) 83
health aspects (81) 81
coronary artery disease - blood (80) 80
stroke (80) 80
adolescent (79) 79
low-dose aspirin (79) 79
flow cytometry (76) 76
artery-disease (75) 75
cell biology (75) 75
platelet reactivity (75) 75
mortality (74) 74
risk assessment (73) 73
prevention (72) 72
biomarkers - blood (71) 71
collagen (71) 71
predictive value of tests (70) 70
research (70) 70
ticlopidine - pharmacology (69) 69
bleeding (68) 68
cardiovascular diseases (68) 68
in-vitro (68) 68
stents (68) 68
acute myocardial-infarction (67) 67
intervention (67) 67
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1519) 1519
German (11) 11
Japanese (9) 9
French (4) 4
Chinese (1) 1
Korean (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Thrombosis and Haemostasis, ISSN 0340-6245, 2014, Volume 112, Issue 6, pp. 1198 - 1208
Adjunctive use of phosphodiesterase (PDE) inhibitor can enhance anti-platelet and vasoprotective properties in patients with cardiovascular disease. The aim of... 
Intervention | Clopidogrel | Platelets | Dipyridamole | clopidogrel | dipyridamole | intervention | CILOSTAZOL | MYOCARDIAL-INFARCTION | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | ASPIRIN PLUS DIPYRIDAMOLE | STIMULATED PHOSPHOPROTEIN PHOSPHORYLATION | STROKE | MAINTENANCE-DOSE CLOPIDOGREL | PERCUTANEOUS CORONARY INTERVENTION | DUAL ANTIPLATELET THERAPY | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | TYPE-2 DIABETES-MELLITUS | Prospective Studies | Ticlopidine - therapeutic use | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Middle Aged | Male | Microfilament Proteins - blood | Percutaneous Coronary Intervention - instrumentation | Phosphoproteins - blood | Cytochrome P-450 CYP3A - genetics | Time Factors | Aspirin - adverse effects | Platelet Function Tests | Ticlopidine - adverse effects | Dipyridamole - adverse effects | Female | Aspirin - therapeutic use | Phosphodiesterase 5 Inhibitors - therapeutic use | Platelet Aggregation - drug effects | Blood Platelets - drug effects | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Dipyridamole - therapeutic use | Stents | Drug Resistance | Republic of Korea | Platelet Aggregation Inhibitors - adverse effects | Cell Adhesion Molecules - blood | Cytochrome P-450 CYP2C19 - genetics | Genotype | Treatment Outcome | Biomarkers - blood | Ticlopidine - analogs & derivatives | Blood Platelets - metabolism | Aged | ATP Binding Cassette Transporter, Sub-Family B - genetics | Percutaneous Coronary Intervention - adverse effects
Journal Article
Journal of Thrombosis and Thrombolysis, ISSN 0929-5305, 2/2013, Volume 35, Issue 2, pp. 165 - 174
Journal Article
Journal of the College of Physicians and Surgeons Pakistan, ISSN 1022-386X, 08/2016, Volume 26, Issue 8, pp. 647 - 650
Journal Article
Journal of the American Heart Association, ISSN 2047-9980, 2015, Volume 4, Issue 10, p. e002203
Journal Article
BBA - General Subjects, ISSN 0304-4165, 11/2017, Volume 1861, Issue 11, pp. 2609 - 2618
The current standard-of-care antiplatelet therapy in cardiovascular disease patients is consisted of cyclooxygenase-1 (COX-1) inhibitor aspirin, along with a... 
Triple quadrupole | Antiplatelet | Naringenin | DHA | Cardiovascular diseases | Plasma stability | PROTEIN | HUMAN LEUKEMIA-CELLS | BIOCHEMISTRY & MOLECULAR BIOLOGY | PLATELET-FUNCTION | BIOCATALYTIC PREPARATION | CORONARY HEART-DISEASE | QUERCETIN | FLAVONOID GLYCOSIDES | BIOPHYSICS | ANTIOXIDANT | EPA | POLYUNSATURATED FATTY-ACIDS | Receptor, PAR-1 - metabolism | Cardiovascular Diseases - drug therapy | Humans | Receptors, Purinergic P2Y12 - drug effects | Flavanones - chemical synthesis | Hemorrhage - prevention & control | Platelet Aggregation Inhibitors - chemical synthesis | Tandem Mass Spectrometry | Computer Simulation | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - blood | Flavonoids - administration & dosage | Aspirin - therapeutic use | Platelet Aggregation - drug effects | Receptors, Purinergic P2Y12 - metabolism | Receptor, PAR-1 - antagonists & inhibitors | Standard of Care | Docosahexaenoic Acids - chemistry | Hemorrhage - blood | Docosahexaenoic Acids - administration & dosage | Flavanones - administration & dosage | Flavonoids - chemical synthesis | Signal Transduction - drug effects | Cyclooxygenase 1 - drug effects | Platelet Activation - drug effects | Cyclooxygenase 1 - metabolism | Hemorrhage - chemically induced | Aspirin | Proteases | Cardiac patients | Isoflavones | Unsaturated fatty acids | Omega-3 fatty acids
Journal Article
Circulation: Cardiovascular Interventions, ISSN 1941-7640, 06/2016, Volume 9, Issue 6, pp. e003612 - e003612
Background-The Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX trial demonstrated superiority of... 
clinical trial | percutaneous coronary intervention | antiplatelet therapy | international comparison | variation | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | PCI | SITES | INSIGHTS | 10194 | 10162 | 10043 | Original | 10149
Journal Article
Journal Article
Molecules, ISSN 1420-3049, 02/2016, Volume 21, Issue 2, p. 168
Nutrients transiently or chronically modulate functional and biochemical characteristics of cells and tissues both in vivo and in vitro. The influence of... 
Peripheral blood leukocytes | Chronic inflammation | Endothelial dysfunction | Human umbilical endothelial vein cells | Nutrients | Inflammation | Macrophages | Innate immune response | peripheral blood leukocytes | BIOCHEMISTRY & MOLECULAR BIOLOGY | PLATELET-FUNCTION | endothelial dysfunction | human umbilical endothelial vein cells | FUNCTION IN-VITRO | CHEMISTRY, MULTIDISCIPLINARY | IL-6 | nutrients | macrophages | DANGER SIGNALS | INHIBITION | inflammation | innate immune response | GENE-EXPRESSION | TNF-ALPHA | EX-VIVO | NF-KAPPA-B | chronic inflammation | Human Umbilical Vein Endothelial Cells | Inflammation - chemically induced | Cytokines - metabolism | Plant Extracts - pharmacology | Humans | Inflammation - immunology | Lipopolysaccharides - adverse effects | Interleukins - metabolism | Endothelial Cells - immunology | Gene Expression Regulation - drug effects | Animals | Tumor Necrosis Factor-alpha - adverse effects | Inflammation - drug therapy | Macrophages - drug effects | RAW 264.7 Cells | Lycopersicon esculentum - chemistry | Mice | Macrophages - immunology | Endothelial Cells - drug effects | Alertness | Adhesion tests | Homeostasis | Inflammatory response | Biochemistry | Leukocytes | Cell adhesion molecules | Cell adhesion & migration | Lipopolysaccharides | Interleukin 6 | Interleukins | IP-10 protein | Tomatoes | Interleukin 8 | Immune system | Adenosine | Cytokines | Intercellular adhesion molecule 1 | Immunoregulation | Interleukin 12 | CCL3 protein | Gene expression | Adhesion | Endothelial cells | Polymerase chain reaction | White blood cells | Nitric oxide | CXCL10 protein | Interleukin 10 | Biochemical characteristics | Human behavior | Monocyte chemoattractant protein 1 | Chemokines
Journal Article